Immuno-oncology is an emerging field that has taken great strides in the fight against cancer, bolstered by a refined understanding of how tumors evade the natural immune response. Leading immuno-oncology researchers are leveraging next-generation sequencing to discover biomarkers and apply genomics to personalized immunotherapy.
Research into the mechanisms tumors use to evade the immune response have led to promising therapeutic targets. These therapies boost the ability of the immune system to target cancer, or limit the tumor’s ability to evade the natural immune response.
Transcriptome analysis is helping to advance cancer immunotherapy research. This white paper demonstrates the performance of TruSeq RNA Access in comparison to a hybridization-based digital counting method for quantitative analysis (NanoString Technologies) of 57 tumor tissue samples.Access PDF
Illumina offers several library preparation and sequencing options with access to data analysis options for Immuno-Oncology Research. Streamlined workflows and flexible kit configurations accommodate multiple study designs.
Approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*
Click on the below to view products for each workflow step.
The TruSeq RNA Access library prep kit provides a low-cost solution for analyzing human RNA isolated from limited or low-quality samples, including FFPE.TruSeq Exome
TruSeq Exome Library Prep Kit is a cost-effective library preparation and exome enrichment solution.
Flexibility and unprecedented throughput for virtually any genome, sequencing method, and scale of project.HiSeq 3000/HiSeq 4000 Systems
Patterned flow cell technology results in high throughput, low price per sample, and enhanced speed and performance.
*Data calculations on file. Illumina, Inc., 2015